Technology Platforms

High Throughput Screening,
DEL & AI-Powered Hit Discovery Services

Accelerate hit discovery through integrated high-throughput screening (HTS) and DNA-encoded library (DEL) capabilities, combining custom assay development, differentiated compound libraries, fit-for-purpose screening strategies, and AI-enabled hit expansion.

From assay development to hit validation and hit-to-lead optimization, our scientists tailor each approach to the biology, target class, and project objectives, enabling the rapid identification of high-confidence hits and informed go/no-go decisions.

Access to the brochure requires submission of this form.

"*" indicates required fields

* Your information will be securely transmitted using SSL encryption.
* By submitting this form, you agree to Axcelead Privacy Notice

Proprietary Compound Library

1.25+ Million

Compound Library

60%

Internally Synthesized Compounds

1 Billion

Proprietary-technology-based DEL

HTS Track Record and Database

480+

Assay Development in 6 Years

35+ Million

Proprietary Database for AI Model

700+

HTS Projects

95%

Hit ID Success Rate

What We Offer

End-to-End Support from Hit Discovery to Hit-to-Lead

Axcelead provides an integrated discovery platform combining cutting-edge technologies, proprietary assets, and deep expertise to deliver high-quality hits and accelerate your programs.

1

Assay Development

  • Custom assay development across diverse target classes
  • Robust, reproducible, HTS-optimized assays
  • Experienced scientists and proven methodologies

Optimized Assays

2

Library Screening (HTS & DEL)

  • HTS with 1.25M+ pharma-origin compounds
  • DEL screening up to 1 billion unique compounds
  • High-quality starting points with broad chemical diversity

Quality Hits

3

Hit Validation

  • Orthogonal and cellular assays
  • Confirm activity, selectivity, and mechanism
  • Generate high-confidence validated hits

Validated Hits

4

AI-Powered Hit Expansion

  • AI and machine learning models trained on proprietary data
  • Prioritize compounds beyond primary activity (selectivity, ADMET, novelty, etc.)
  • Expand chemical space efficiently

Prioritized Hits

5

Hit-to-Lead Support

  • Early SAR exploration
  • ADMET assessment and risk profiling
  • Support for lead optimization readiness

Lead Candidates

WHEN TO CHOOSE AXCELEAD

When to Consider Axcelead’s HTS Platform

Axcelead is best suited for programs that need differentiated starting points, high-confidence screening, and data-driven hit prioritization.

Leverage proprietary pharma-origin compounds to discover novel starting points and enable new chemical series.

Best for programs that:

  • Need first-in-class or novel chemical matter
  • Have limited starting points in-house
Access focused libraries for specific target classes and emerging modalities, including GPCR, kinase, TPD, and RNA-targeting discovery.

Best for programs that:

  • Need a library tailored to a specific target class
  • Explore emerging modalities such as TPD and molecular glues
Use our proprietary DEL technology to achieve reliable binder identification with reduced non-specific hits.

Best for programs that:

  • Need high-confidence binders from large chemical spaces
  • Want to minimize non-specific and false-positive hits
Apply AI and proprietary data to prioritize compounds that balance activity, selectivity, ADMET risk, and chemical novelty.

Best for programs that:

  • Need to make smarter go/no-go decisions
  • Seek to accelerate hit-to-lead progression with data-driven insights

CLIENT PERSPECTIVES

Trusted by Leading Organizations Worldwide

Client feedback on assay development, hit identification, and screening data quality.

Ready to Discuss Your Hit Discovery Project?

Our scientists are ready to help design the right HTS, library screening, or hit identification strategy for your drug discovery program.

Access to the brochure requires submission of this form.

"*" indicates required fields

* Your information will be securely transmitted using SSL encryption.
* By submitting this form, you agree to Axcelead Privacy Notice